This compound is primarily utilized in the field of biomedical research, particularly in the development of targeted protein degradation technologies. It serves as a key component in PROTAC (Proteolysis Targeting Chimeras) molecules, which are designed to selectively degrade disease-causing proteins within cells. By facilitating the recruitment of E3 ubiquitin ligases to specific target proteins, it enables their ubiquitination and subsequent degradation by the proteasome. This mechanism is especially valuable in studying and potentially treating conditions such as cancer, neurodegenerative diseases, and other disorders driven by aberrant protein activity. Additionally, its structure allows for enhanced cellular permeability and binding efficiency, making it a valuable tool in drug discovery and therapeutic development.